122 related articles for article (PubMed ID: 32544801)
1. Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study.
Myklebust TÅ; Andersson T; Bardot A; Vernon S; Gavin A; Fitzpatrick D; Jerm MB; Rutherford M; Parkin DM; Sasieni P; Arnold M; Soerjomataram I; Bray F; Lambert PC; Møller B
Cancer Epidemiol; 2020 Aug; 67():101759. PubMed ID: 32544801
[TBL] [Abstract][Full Text] [Related]
2. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.
Arnold M; Rutherford MJ; Bardot A; Ferlay J; Andersson TM; Myklebust TÅ; Tervonen H; Thursfield V; Ransom D; Shack L; Woods RR; Turner D; Leonfellner S; Ryan S; Saint-Jacques N; De P; McClure C; Ramanakumar AV; Stuart-Panko H; Engholm G; Walsh PM; Jackson C; Vernon S; Morgan E; Gavin A; Morrison DS; Huws DW; Porter G; Butler J; Bryant H; Currow DC; Hiom S; Parkin DM; Sasieni P; Lambert PC; Møller B; Soerjomataram I; Bray F
Lancet Oncol; 2019 Nov; 20(11):1493-1505. PubMed ID: 31521509
[TBL] [Abstract][Full Text] [Related]
3. Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2.
Andersson TM; Myklebust TÅ; Rutherford MJ; Møller B; Arnold M; Soerjomataram I; Bray F; Parkin DM; Lambert PC
Br J Cancer; 2022 May; 126(8):1224-1228. PubMed ID: 35058590
[TBL] [Abstract][Full Text] [Related]
4. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
5. Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions.
Eden M; Harrison S; Griffin M; Lambe M; Pettersson D; Gavin A; Brewster DH; Lin Y; Johannesen TB; Milne RL; Farrugia H; Nishri D; King MJ; Huws DW; Warlow J; Turner D; Earle CC; Peake M; Rashbass J
Cancer Epidemiol; 2019 Feb; 58():184-192. PubMed ID: 30639877
[TBL] [Abstract][Full Text] [Related]
6. International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study).
Arnold M; Morgan E; Bardot A; Rutherford MJ; Ferlay J; Little A; Møller B; Bucher O; De P; Woods RR; Saint-Jacques N; Gavin AT; Engholm G; Achiam MP; Porter G; Walsh PM; Vernon S; Kozie S; Ramanakumar AV; Lynch C; Harrison S; Merrett N; O'Connell DL; Mala T; Elwood M; Zalcberg J; Huws DW; Ransom D; Bray F; Soerjomataram I
Gut; 2022 Aug; 71(8):1532-1543. PubMed ID: 34824149
[TBL] [Abstract][Full Text] [Related]
7. Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study.
Andersson TM; Rutherford MJ; Myklebust TÅ; Møller B; Soerjomataram I; Arnold M; Bray F; Parkin DM; Sasieni P; Bucher O; De P; Engholm G; Gavin A; Little A; Porter G; Ramanakumar AV; Saint-Jacques N; Walsh PM; Woods RR; Lambert PC
Br J Cancer; 2021 Mar; 124(5):1026-1032. PubMed ID: 33293692
[TBL] [Abstract][Full Text] [Related]
8. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project).
Araghi M; Arnold M; Rutherford MJ; Guren MG; Cabasag CJ; Bardot A; Ferlay J; Tervonen H; Shack L; Woods RR; Saint-Jacques N; De P; McClure C; Engholm G; Gavin AT; Morgan E; Walsh PM; Jackson C; Porter G; Møller B; Bucher O; Eden M; O'Connell DL; Bray F; Soerjomataram I
Gut; 2021 Jan; 70(1):114-126. PubMed ID: 32482683
[TBL] [Abstract][Full Text] [Related]
9. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study.
McPhail S; Barclay ME; Johnson SA; Swann R; Alvi R; Barisic A; Bucher O; Creighton N; Denny CA; Dewar RA; Donnelly DW; Dowden JJ; Downie L; Finn N; Gavin AT; Habbous S; Huws DW; May L; McClure CA; Møller B; Musto G; Nilssen Y; Saint-Jacques N; Sarker S; Shack L; Tian X; Thomas RJS; Thomson CS; Wang H; Woods RR; You H; Lyratzopoulos G;
Lancet Oncol; 2024 Mar; 25(3):338-351. PubMed ID: 38423048
[TBL] [Abstract][Full Text] [Related]
10. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study.
McPhail S; Barclay ME; Swann R; Johnson SA; Alvi R; Barisic A; Bucher O; Creighton N; Denny CA; Dewar RA; Donnelly DW; Dowden JJ; Downie L; Finn N; Gavin AT; Habbous S; Huws DW; Kumar SE; May L; McClure CA; Morrison DS; Møller B; Musto G; Nilssen Y; Saint-Jacques N; Sarker S; Shack L; Tian X; Thomas RJ; Wang H; Woods RR; You H; Zhang B; Lyratzopoulos G;
Lancet Oncol; 2024 Mar; 25(3):352-365. PubMed ID: 38423049
[TBL] [Abstract][Full Text] [Related]
11. The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project).
Morgan E; Arnold M; Rutherford MJ; Bardot A; Ferlay J; De P; Engholm G; Jackson C; Little A; Saint-Jacques N; Walsh P; Woods RR; O'Connell DL; Bray F; Parkin DM; Soerjomataram I
Int J Cancer; 2021 Sep; 149(5):1013-1020. PubMed ID: 33932300
[TBL] [Abstract][Full Text] [Related]
12. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
13. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
Cabasag CJ; Butler J; Arnold M; Rutherford M; Bardot A; Ferlay J; Morgan E; Møller B; Gavin A; Norell CH; Harrison S; Saint-Jacques N; Eden M; Rous B; Nordin A; Hanna L; Kwon J; Cohen PA; Altman AD; Shack L; Kozie S; Engholm G; De P; Sykes P; Porter G; Ferguson S; Walsh P; Trevithick R; Tervonen H; O'Connell D; Bray F; Soerjomataram I
Gynecol Oncol; 2020 Apr; 157(1):234-244. PubMed ID: 32005583
[TBL] [Abstract][Full Text] [Related]
14. Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India.
Yeole BB; Kumar AV
Asian Pac J Cancer Prev; 2004; 5(2):175-82. PubMed ID: 15244521
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study.
McPhail S; Swann R; Johnson SA; Barclay ME; Abd Elkader H; Alvi R; Barisic A; Bucher O; Clark GRC; Creighton N; Danckert B; Denny CA; Donnelly DW; Dowden JJ; Finn N; Fox CR; Fung S; Gavin AT; Gomez Navas E; Habbous S; Han J; Huws DW; Jackson CGCA; Jensen H; Kaposhi B; Kumar SE; Little AL; Lu S; McClure CA; Møller B; Musto G; Nilssen Y; Saint-Jacques N; Sarker S; Te Marvelde L; Thomas RS; Thomas RJS; Thomson CS; Woods RR; Zhang B; Lyratzopoulos G;
Lancet Oncol; 2022 May; 23(5):587-600. PubMed ID: 35397210
[TBL] [Abstract][Full Text] [Related]
16. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study.
Araghi M; Fidler-Benaoudia M; Arnold M; Rutherford M; Bardot A; Ferlay J; Bucher O; De P; Engholm G; Gavin A; Kozie S; Little A; Møller B; St Jacques N; Tervonen H; Walsh P; Woods R; O'Connell DL; Baldwin D; Elwood M; Siesling S; Bray F; Soerjomataram I; ; ; ; ;
Thorax; 2022 Apr; 77(4):378-390. PubMed ID: 34282033
[TBL] [Abstract][Full Text] [Related]
17. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.
Coleman MP; Forman D; Bryant H; Butler J; Rachet B; Maringe C; Nur U; Tracey E; Coory M; Hatcher J; McGahan CE; Turner D; Marrett L; Gjerstorff ML; Johannesen TB; Adolfsson J; Lambe M; Lawrence G; Meechan D; Morris EJ; Middleton R; Steward J; Richards MA;
Lancet; 2011 Jan; 377(9760):127-38. PubMed ID: 21183212
[TBL] [Abstract][Full Text] [Related]
18. A way to explore the existence of "immortals" in cancer registry data - An illustration using data from ICBP SURVMARK-2.
Andersson TM; Rutherford MJ; Myklebust TÅ; Møller B; Arnold M; Soerjomataram I; Bray F; Elkader HA; Engholm G; Huws D; Little A; Shack L; Walsh PM; Woods RR; Parkin DM; Lambert PC
Cancer Epidemiol; 2022 Feb; 76():102085. PubMed ID: 34954495
[TBL] [Abstract][Full Text] [Related]
19. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
Allemani C; Weir HK; Carreira H; Harewood R; Spika D; Wang XS; Bannon F; Ahn JV; Johnson CJ; Bonaventure A; Marcos-Gragera R; Stiller C; Azevedo e Silva G; Chen WQ; Ogunbiyi OJ; Rachet B; Soeberg MJ; You H; Matsuda T; Bielska-Lasota M; Storm H; Tucker TC; Coleman MP;
Lancet; 2015 Mar; 385(9972):977-1010. PubMed ID: 25467588
[TBL] [Abstract][Full Text] [Related]
20. Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
Rutherford MJ; Arnold M; Bardot A; Ferlay J; De P; Tervonen H; Little A; Bucher O; St Jacques N; Gavin A; Engholm G; Møller B; O'Connell DL; Merrett N; Parkin DM; Bray F; Soerjomataram I
Int J Cancer; 2021 Dec; 149(12):2020-2031. PubMed ID: 34460109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
